Los puntos clave no están disponibles para este artículo en este momento.
Current recommendations for prostate-specific antigen testing are reviewed, as well as the initial results of two randomized trials. The potential risks of screening, including morbidity from overdiagnosis and overtreatment, are described.
Richard M. Hoffman (Wed,) studied this question.